CLOVERNA, the first startup from Kawasaki Medical School, is a bio-startup that will change the future by realizing high-precision and high-speed RNA drug discovery based on the world's only RNA target drug discovery technology. In recent years, non-coding RNA (ncRNA) has been found to play an important role in elucidating the causes of cancer development, malignant transformation, metastasis, and diseases caused by the accumulation of abnormal proteins such as amyotrophic lateral sclerosis and dilated cardiomyopathy. However, various issues have made it difficult to analyze the functions of ncRNA. CLOVERNA's technology enables the functional analysis of ncRNAs and the recognition of drug discovery targets, and is expected to create new treatment opportunities for these intractable diseases.